ESTRO 2025 - Abstract Book

S883

Clinical - Gynaecology

ESTRO 2025

Bethesda, USA. 16 Radiation Oncology, University of Pennsylvania, Philadelphia, USA. 17 Radiation Oncology, Royal Marsden Hospital, London, United Kingdom. 18 Radiation Oncology, MD Anderson Cancer Center, Texas, USA

Purpose/Objective: Cervical cancer is the leading cause of cancer-related morbidity and mortality in Uganda. This study aimed to describe cervical cancer treatment outcomes and survival rates at a single tertiary oncology institution in Uganda. Material/Methods: A retrospective study was conducted among women with histologically confirmed cervical cancer treated at the Uganda Cancer Institute from January 2018 to December 2022. Data collected included demographics, HIV status, stage, treatment modalities, and survival outcomes. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), recurrence patterns, and predictors of treatment completion and survival. Kaplan-Meier survival estimates and Cox regression analyses were used for statistical evaluations. Results: Between 2018 and 2022, 2074 patients with cervical cancer were treated. The median age was 50 years (range 18– 91), and most presented with stage III disease (91.3%, n=1894). The median duration from onset of symptoms to diagnosis was 72 days (range 30 – 310). Histology revealed squamous cell carcinoma in 99.4% (n=2054). Among all patients, 56.7% (n=1174) were treated with radical intent, with mostly primary chemoradiation. Only 7.9% completed treatment within 56 days. Two-year OS for patients treated with radical intent was 97% (95% CI: 96–98%), with OS varying by stage: 100% (stage I), 85.7% (stage II), 93% (stage III), and 80% (stage IV). At two years, recurrence was reported in 18 cases, primarily in pelvic and para-aortic lymph nodes. Independent predictors of OS included hemoglobin≥10 g/dL (HR 0.26; 95% CI: 0.10–0.68, p=0.006), while incomplete brachytherapy (HR 2.45; 95% CI: 1.22– 4.89, p=0.014) and advanced stage (HR 3.25; 95% CI: 1.82–5.78, p<0.001) were significant predictors of recurrence. Conclusion: This study highlights significant challenges in achieving optimal treatment outcomes for cervical cancer patients in Uganda, particularly in brachytherapy access and treatment completion. Despite promising survival outcomes for those treated with radical intent, delays in diagnosis and suboptimal treatment rates remain critical barriers. Addressing these gaps through improved access to timely radiotherapy, enhanced diagnostic capabilities, and comprehensive patient support is essential to improving cervical cancer outcomes in Uganda.

Keywords: Cervical cancer, Treatment Outcomes, Uganda.

References: Najjemba, J.I., Ndagire, R., Mulamira, P. et al. Treatment compliance among adult cervical cancer patients receiving care at Uganda Cancer Institute, Uganda: a retrospective data review. BMC Cancer 23 , 631 (2023). https://doi.org/10.1186/s12885-023-11145-1

4405

Digital Poster Oncologic outcomes and toxicity profile of EBRT and HDR-BT in locally advanced cervical cancer: A single center retrospective study. Frandeina Pinto G. 1 , Ana L Rivero P. 1 , Paola A Navarrete 1 , Maria P Galdós 1 , Javier Anchuelo 2 , Amaia Ilundain 1 , Javier Albendea 1 , Mara García 1 , Francisco J Olloqui 1 , Cristina Rodriguez A 1 , Alejandra Perez 1 , Marina Gutierrez 1 , Ana Reguilon 1 , Rosa Fabregat 1 , Jose A Vazquez 1 , Noelia Suarez 1 , Paula Delgado 1 , Rodrigo Astudillo 3 , Javier Uzquiza 1 , Iván Diaz de Cerio 1 , Uriel A Corro 1 , Patricia Sarrión 1 , Juan I Raba 1 , Maria T Pachecho 1 , Pedro J Prada 1